Abstract
Large scale toxicological testing programmes which are currently ongoing such as the new European chemical legislation REACH require the development of new integrated testing strategies rather than applying traditional testing schemes to thousands of chemicals. The current practice of requiring in vivo testing for every possible adverse effect endanger the success of these programmes due (i) to limited testing facilities and sufficient capacity of scientific/technical knowledge for reproductive toxicity; (ii) an unacceptable number of laboratory animals involved (iii) an intolerable number of chemicals classified as false positive. A key aspect of the implementation of new testing strategies is the determination of prevalence of reproductive toxicity in the universe of industrial chemicals. Prevalences are relevant in order to be aware on the expected rate of false classification during the toxicological testing and to implement appropriate measures for their avoidance. Furthermore, a detailed understanding on the subendpoints affected by reproductive toxicants and the underlying mechanisms will lead to more science based testing strategies integrating alternative methods without compromising the protection of consumers.
Keywords: REACH, reproductive toxicity, prevalence, alternative methods, validation, ReProTect
Current Pharmaceutical Design
Title: The Development of New Concepts for Assessing Reproductive Toxicity Applicable to Large Scale Toxicological Programmes
Volume: 13 Issue: 29
Author(s): S. Bremer, C. Pellizzer, S. Hoffmann, T. Seidle and T. Hartung
Affiliation:
Keywords: REACH, reproductive toxicity, prevalence, alternative methods, validation, ReProTect
Abstract: Large scale toxicological testing programmes which are currently ongoing such as the new European chemical legislation REACH require the development of new integrated testing strategies rather than applying traditional testing schemes to thousands of chemicals. The current practice of requiring in vivo testing for every possible adverse effect endanger the success of these programmes due (i) to limited testing facilities and sufficient capacity of scientific/technical knowledge for reproductive toxicity; (ii) an unacceptable number of laboratory animals involved (iii) an intolerable number of chemicals classified as false positive. A key aspect of the implementation of new testing strategies is the determination of prevalence of reproductive toxicity in the universe of industrial chemicals. Prevalences are relevant in order to be aware on the expected rate of false classification during the toxicological testing and to implement appropriate measures for their avoidance. Furthermore, a detailed understanding on the subendpoints affected by reproductive toxicants and the underlying mechanisms will lead to more science based testing strategies integrating alternative methods without compromising the protection of consumers.
Export Options
About this article
Cite this article as:
Bremer S., Pellizzer C., Hoffmann S., Seidle T. and Hartung T., The Development of New Concepts for Assessing Reproductive Toxicity Applicable to Large Scale Toxicological Programmes, Current Pharmaceutical Design 2007; 13 (29) . https://dx.doi.org/10.2174/138161207782110462
DOI https://dx.doi.org/10.2174/138161207782110462 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cardiovascular Risk Calculators and their Applicability to South Asians
Current Diabetes Reviews Antibacterial Combination of Oleoresin from Copaifera multijuga Hayne and Biogenic Silver Nanoparticles Towards Streptococcus agalactiae
Current Pharmaceutical Biotechnology Effect of Fasting Ramadan in Diabetes Control Status - Application of Extensive Diabetes Education, Serum Creatinine with HbA1c Statistical ANOVA and Regression Models to Prevent Hypoglycemia
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) CTLA-4Ig: Uses and Future Directions
Recent Patents on Inflammation & Allergy Drug Discovery PUFA for Human Health: Diet or Supplementation?
Current Pharmaceutical Design Signal Transduction Pathways of Inflammatory Gene Expressions and Therapeutic Implications
Current Pharmaceutical Design Statins and Protein Prenylation in Cancer Cell Biology and Therapy
Anti-Cancer Agents in Medicinal Chemistry Loading of Propranolol Hydrochloride on MCF and Sustained Release
Micro and Nanosystems Developments in Non-Surgical Therapies for Abdominal Aortic Aneurysm
Current Vascular Pharmacology Cardiovascular Disease Burden and Risk Factors Before and After Kidney Transplant
Cardiovascular & Hematological Disorders-Drug Targets Oxidative Stress and Antioxidative Enzyme Activities in Chronic Kidney Disease and Different Types of Renal Replacement Therapy
Current Protein & Peptide Science Mediterranean Diet Polyphenols: Anthocyanins and Their Implications for Health
Mini-Reviews in Medicinal Chemistry Update on Anti-TNF-Alpha Treatment in Rheumatic Diseases
Current Drug Therapy Gene Therapy Targeting Inflammation in Atherosclerosis
Current Pharmaceutical Design Coronary CT Angiography in the Diagnosis of Coronary Artery Disease
Current Medical Imaging LINE-1 Methylation is Associated with an Increased Risk of Ischemic Stroke in Men
Current Neurovascular Research Current Nanotechnological Approaches for an Effective Delivery of Bioactive Drug Molecules to Overcome Drug Resistance Tuberculosis
Current Pharmaceutical Design Recent Advances in Exercise Testing
Current Cardiology Reviews Employment of Quality by Design Approach via Response Surface Methodology to Optimize and Develop Modified-release Formulation of Hydrochlorothiazide
Current Computer-Aided Drug Design β-Lactam Cholesterol Absorption Inhibitors
Current Medicinal Chemistry